First Trust Advisors LP trimmed its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 38.4% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 158,732 shares of the company’s stock after selling 98,878 shares during the quarter. First Trust Advisors LP’s holdings in IDEXX Laboratories were worth $24,823,000 as of its most recent filing with the Securities and Exchange Commission.
Several other institutional investors and hedge funds have also bought and sold shares of the company. Sei Investments Co. raised its stake in shares of IDEXX Laboratories by 28.4% in the fourth quarter. Sei Investments Co. now owns 55,806 shares of the company’s stock valued at $8,727,000 after purchasing an additional 12,360 shares in the last quarter. Old Mutual Global Investors UK Ltd. raised its stake in shares of IDEXX Laboratories by 19.8% in the fourth quarter. Old Mutual Global Investors UK Ltd. now owns 995,156 shares of the company’s stock valued at $155,622,000 after purchasing an additional 164,777 shares in the last quarter. Catalyst Capital Advisors LLC raised its stake in shares of IDEXX Laboratories by 2.3% in the fourth quarter. Catalyst Capital Advisors LLC now owns 17,600 shares of the company’s stock valued at $2,752,000 after purchasing an additional 400 shares in the last quarter. Sentry Investment Management LLC acquired a new position in shares of IDEXX Laboratories in the fourth quarter valued at $1,086,000. Finally, Bronfman E.L. Rothschild L.P. raised its stake in shares of IDEXX Laboratories by 178.2% in the fourth quarter. Bronfman E.L. Rothschild L.P. now owns 1,928 shares of the company’s stock valued at $302,000 after purchasing an additional 1,235 shares in the last quarter. 86.02% of the stock is owned by institutional investors.
In other news, VP Brian P. Mckeon sold 6,602 shares of the firm’s stock in a transaction on Monday, February 5th. The stock was sold at an average price of $181.36, for a total value of $1,197,338.72. Following the completion of the sale, the vice president now directly owns 47,040 shares in the company, valued at $8,531,174.40. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Giovani Twigge sold 2,000 shares of the firm’s stock in a transaction on Thursday, November 30th. The shares were sold at an average price of $156.07, for a total value of $312,140.00. The disclosure for this sale can be found here. Insiders have sold 86,762 shares of company stock valued at $15,202,484 over the last quarter. Corporate insiders own 2.77% of the company’s stock.
A number of research analysts recently commented on the company. Piper Jaffray Companies upped their target price on IDEXX Laboratories to $211.00 and gave the company an “overweight” rating in a research note on Thursday, February 1st. Bank of America increased their price objective on IDEXX Laboratories from $200.00 to $220.00 and gave the stock a “buy” rating in a research note on Friday, February 2nd. BidaskClub upgraded IDEXX Laboratories from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, January 31st. Zacks Investment Research lowered IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Wednesday, January 31st. Finally, Canaccord Genuity reiterated a “buy” rating and set a $210.00 price objective on shares of IDEXX Laboratories in a research note on Monday, January 29th. One research analyst has rated the stock with a sell rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $194.00.
IDEXX Laboratories, Inc. (NASDAQ:IDXX) opened at $183.86 on Friday. The company has a debt-to-equity ratio of -11.26, a quick ratio of 0.80 and a current ratio of 0.97. IDEXX Laboratories, Inc. has a 12 month low of $141.02 and a 12 month high of $198.73. The stock has a market capitalization of $16,025.37, a price-to-earnings ratio of 58.21, a price-to-earnings-growth ratio of 2.26 and a beta of 0.58.
IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings data on Thursday, February 1st. The company reported $0.77 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.73 by $0.04. IDEXX Laboratories had a negative return on equity of 432.19% and a net margin of 13.36%. The firm had revenue of $506.00 million during the quarter, compared to analyst estimates of $490.51 million. During the same period in the prior year, the company posted $0.58 earnings per share. The business’s revenue for the quarter was up 14.2% compared to the same quarter last year. equities analysts anticipate that IDEXX Laboratories, Inc. will post 4.09 EPS for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: “First Trust Advisors LP Trims Stake in IDEXX Laboratories, Inc. (IDXX)” was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this piece can be read at https://www.dispatchtribunal.com/2018/02/23/first-trust-advisors-lp-trims-stake-in-idexx-laboratories-inc-idxx.html.
IDEXX Laboratories Company Profile
IDEXX Laboratories, Inc develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. The Company also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market.
Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX).
Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.